COSMO Pharmaceuticals N.V.
COPN | SW
Overview
Corporate Details
- ISIN(s):
- NL0011832936
- LEI:
- 724500OX0EBQRYTVV639
- Country:
- Netherlands
- Address:
- Sir Rogerson's Quay Riverside II, Dublin 2 Dublin
- Website:
- https://www.cosmopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing therapies for gastrointestinal (GI) diseases, dermatology, and health tech. The company's primary therapeutic focus is on the oral and endoscopic treatment of colon diseases, including bowel diseases and colorectal cancer prevention, leveraging its proprietary MMX® technology platform. In addition to its product pipeline, Cosmo provides comprehensive manufacturing services for solid, semi-solid, and liquid oral medicines. These services encompass manufacturing process assessment, technology transfer, product stability evaluation, testing, market release, and the drafting of necessary regulatory documentation for other pharmaceutical firms.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for COSMO Pharmaceuticals N.V..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-08 02:00 |
Regulatory News Service
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of O…
|
English | 4.7 KB | |
| 2025-08-08 02:00 |
M&A Activity
Cosmo und Takeda verlängern ihre strategische Produktionsvereinbarung für die w…
|
German | 5.0 KB | |
| 2025-08-06 02:00 |
Business and Financial Review
Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffir…
|
English | 3.3 KB | |
| 2025-08-06 02:00 |
Earnings Release
Cosmo Pharmaceuticals bestätigt, dass keine Auswirkungen durch geplante US-Zöll…
|
German | 4.0 KB | |
| 2025-07-23 02:00 |
Earnings Release
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance …
|
English | 22.3 KB | |
| 2025-07-23 02:00 |
Earnings Release
Cosmo liefert starke Ergebnisse im ersten Halbjahr 2025, erhöht EBITDA-Guidance…
|
German | 24.4 KB | |
| 2025-07-17 02:00 |
Regulatory News Service
Cosmo announces launch of Winlevi® for Treatment of Acne in Singapore and Malay…
|
English | 9.5 KB | |
| 2025-07-17 02:00 |
Regulatory News Service
Cosmo: Markteinführung von Winlevi® zur Behandlung von Akne in Singapur und Mal…
|
German | 10.7 KB | |
| 2025-07-16 02:00 |
Environmental & Social Information
Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact…
|
English | 6.4 KB | |
| 2025-07-16 02:00 |
Environmental & Social Information
Cosmo baut Vorreiterrolle im Bereich ESG durch bedeutende Rating-Upgrades, die …
|
German | 7.4 KB | |
| 2025-07-01 02:00 |
Investor Presentation
Cosmo Unveils Bold 2030 Vision and Strategy; launches AI-driven Growth Phase at…
|
English | 8.4 KB | |
| 2025-07-01 02:00 |
Investor Presentation
Cosmo präsentiert mutige Vision und Strategie für 2030 und leitet am Investoren…
|
German | 9.5 KB | |
| 2025-06-25 02:00 |
M&A Activity
Cosmo Announces Sale of “Digital Trust” in Strategic Portfolio Streamlining Move
|
English | 6.8 KB | |
| 2025-06-25 02:00 |
M&A Activity
Cosmo gibt Verkauf von «Digital Trust» im Rahmen einer strategischen Portfolio-…
|
German | 7.4 KB | |
| 2025-06-24 02:00 |
Regulatory News Service
Cosmo to Unveil First-of-its-Kind Clinical Study on the Use of GI Genius™ with …
|
English | 8.7 KB |
Automate Your Workflow. Get a real-time feed of all COSMO Pharmaceuticals N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for COSMO Pharmaceuticals N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
